Format

Send to

Choose Destination
Nat Commun. 2016 Dec 22;7:13817. doi: 10.1038/ncomms13817.

Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt.

Author information

1
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea.
2
College of Medicine, Hanyang University, Seoul 04763, Korea.
3
Department of Pediatrics, Division of Hematology-Oncology, Weill Cornell Medical College, New York, New York 10021, USA.
4
IZKF and Department of Internal Medicine III, University Hospital Aachen, Aachen 52074, Germany.

Abstract

Hepatic stellate cell (HSC) activation on liver injury facilitates fibrosis. Hepatokines affecting HSCs are largely unknown. Here we show that hepcidin inhibits HSC activation and ameliorates liver fibrosis. We observe that hepcidin levels are inversely correlated with exacerbation of fibrosis in patients, and also confirm the relationship in animal models. Adenoviral delivery of hepcidin to mice attenuates liver fibrosis induced by CCl4 treatment or bile duct ligation. In cell-based assays, either hepcidin from hepatocytes or exogenous hepcidin suppresses HSC activation by inhibiting TGFβ1-mediated Smad3 phosphorylation via Akt. In activated HSCs, ferroportin is upregulated, which can be prevented by hepcidin treatment. Similarly, ferroportin knockdown in HSCs prohibits TGFβ1-inducible Smad3 phosphorylation and increases Akt phosphorylation, whereas ferroportin over-expression has the opposite effect. HSC-specific ferroportin deletion also ameliorates liver fibrosis. In summary, hepcidin suppresses liver fibrosis by impeding TGFβ1-induced Smad3 phosphorylation in HSCs, which depends on Akt activated by a deficiency of ferroportin.

Conflict of interest statement

S.R. is a consultant for Isis, Bayer A.G., Merganser Biotech and Novartis Pharmaceuticals. He also holds an equity/ownership interest in Merganser Biotech and is a co-inventor for patents US8058061 B2 C12N 20111115 and US7541179 B2 C12N 20090602 about the generation of lentiviral vectors for the cure of hemoglobinopathies. The remaining authors declare no competing interests.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center